CA
MRNA icon

Continuum Advisory’s Moderna MRNA Stock Holding History

Continuum Advisory’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.54K Buy
+122
New +$6.31K ﹤0.01% 1306
2025
Q2 		– Sell
-127
Closed -$3.6K – 1138
2025
Q1 		$3.6K Sell
127
-32
-20% -$1.14K ﹤0.01% 1180
2024
Q4 		$6.61K Sell
159
-1
-0.6% -$48 ﹤0.01% 1080
2024
Q3 		$6.36K Buy
160
+14
+10% +$1.28K ﹤0.01% 1100
2024
Q2 		$17.3K Buy
146
+8
+6% +$1.01K ﹤0.01% 817
2024
Q1 		$16.9K Buy
+138
New +$13.9K ﹤0.01% 812
2023
Q4 		– Sell
-2,206
Closed -$228K – 474
2023
Q3 		$228K Sell
2,206
-215
-9% -$24K 0.04% 404
2023
Q2 		$294K Sell
2,421
-616
-20% -$82.2K 0.05% 369
2023
Q1 		$466K Sell
3,037
-324
-10% -$53.4K 0.08% 270
2022
Q4 		$604K Sell
3,361
-89
-3% -$14.6K 0.11% 223
2022
Q3 		$408K Buy
3,450
+390
+13% +$59.2K 0.07% 272
2022
Q2 		$437K Sell
3,060
-460
-13% -$65.8K 0.08% 273
2022
Q1 		$473K Buy
3,520
+495
+16% +$83.3K 0.09% 250
2021
Q4 		$768K Buy
3,025
+697
+30% +$204K 0.17% 138
2021
Q3 		$896K Buy
2,328
+75
+3% +$27.7K 0.24% 98
2021
Q2 		$529K Buy
2,253
+502
+29% +$89.7K 0.16% 140
2021
Q1 		$280K Buy
+1,751
New +$254K 0.12% 143

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Continuum Advisory's MRNA Position: Q2 2026 in Review

Continuum Advisory opened a new position in Moderna (MRNA) in Q2 2026: 122 shares worth $8.54K. The stake represents ﹤0.01% of the portfolio and ranks #1306 among its holdings. This is a return to the name: Continuum Advisory previously reported a position in MRNA as recently as Q1 2025.

Continuum Advisory first reported a position in MRNA in Q1 2021 and has held it in 17 quarters since. The position peaked at $896K in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Continuum Advisory held 122 shares of Moderna worth $8.54K as of Q2 2026.
  • Moderna was a new Continuum Advisory position in Q2 2026.
  • Moderna made up ﹤0.01% of Continuum Advisory's portfolio in Q2 2026, its #1306 holding.
  • Continuum Advisory first reported a position in Moderna in Q1 2021 and has held it in 17 quarters since.
  • Continuum Advisory's Moderna position peaked at $896K in Q3 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.